Device Trial Radar · NCT06405984
Trans-Abdominal Fetal Pulse Oximetry - EFS-IDE
Last checked: Nov 20, 2026Latest source record: Oct 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
35
Actual
Start
Apr 15, 2024
Primary completion
Oct 17, 2025
Study completion Oct 17, 2025
Sponsor
- Lead sponsor
- Raydiant Oximetry, Inc.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- National Institutes of Health (NIH); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- First posted
- May 9, 2024
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Device feasibility
- FDA-regulated device
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The Lumerah System, developed and manufactured by Raydiant Oximetry, Inc., is a non-invasive fetal pulse oximeter that measures fetal arterial oxygen saturation using safe, non-invasive, transabdominal near-infrared spectroscopy. The Lumerah System is intended as an adjunct to cardiotocography. In this study, women in labor will also be simultaneously monitored with a re-engineered version of the previously approved transvaginal oximeter sensor connected to a Nellcor N-400 fetal oximetry monitor for the purposes of device development. The data obtained from the transabdominal sensor and the transvaginal sensor will be used for research purposes only and will not be used to guide or alter patient management.
Conditions
- Fetal Hypoxia
- Fetal Distress
- Fetal Conditions
- Fetal Complications
- Labor Fetal Anoxia
- Labor (Obstetrics)--Complications
- Oxygen Deficiency
Interventions
Fetal Oxygenation MeasurementsDevice
The Lumerah device, and Oxiplex ISS will be positioned on the maternal abdomen in various locations depending on the sonographic evaluation. The transvaginal sensor will be placed after rupture of the maternal membranes and appropriate descent of the fetus.This study is for data collection purposes only. Neonates of this study arm will also be monitored with the Oxiplex ISS system. This study is for data collection purposes only.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Feasibility of monitoring fetal signals.Time frame: During labor for up to 6 hours
1 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sentara Norfolk General - Eastern Virginia Medical School
Norfolk, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.